J&J To Pay States $181M Over Deceptive Risperdal Marketing

By Sean McLernon (August 30, 2012, 3:17 PM EDT) -- Johnson & Johnson agreed Thursday to pay $181 million to 36 states and Washington, D.C., to resolve claims that it deceptively marketed its antipsychotic drugs Risperdal and Invega in what the states are calling the largest-ever multistate consumer protection settlement with a pharmaceutical company.

Under the terms of consent decrees filed in each of the 37 jurisdictions, J&J agreed to change how it promotes and markets the products and stop distributing unsolicited information describing any off-label or unapproved use of the drug, in addition to handing out designated payments to the participating states.

The agreement, which was disclosed by the company...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!